Corporate | 9 May 2011 07:53

STRATEC tightens 2011 revenue forecast

STRATEC Biomedical AG / Key word(s): Change in Forecast/Change in Forecast

09.05.2011 / 07:53

STRATEC tightens 2011 revenue forecast

– 2011 revenues now expected to be between EUR 114 million and EUR 123 million
(previously: between EUR 110 million and EUR 123 million)

– Unchanged EBIT margin of at least 18.5% in 2011

Birkenfeld, May 9, 2011

STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, TecDAX) today announces a tightening of its 2011 revenue guidance based on additional and more detailed ordering information from its customers.

Based on more detailed forecasts received over the last several weeks, and on the latest statements by our customers, STRATEC today provides a tighter guidance range for sales in 2011. Specifically, STRATEC today raises the lower bound of the guidance range and expects to generate sales of at least EUR 114 million in 2011. As previously announced, achievement of the upper end of the expected range (up to EUR 123 million) depends on the precise timing of new and follow-up market launches, and demand for marketed systems.

STRATEC's medium-term guidance, for the period from 2011 to 2013, remains unaffected. Accordingly, STRATEC continues to expect, based on 2010 results, average sales growth (CAGR) of at least 17% over these three years with an EBIT margin of at least 18.5% in 2011 and no less than 19.0% in both 2012 and 2013.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG as well as subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir@stratec.com
www.stratec.com

End of Corporate News

09.05.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:	English
Company:	STRATEC Biomedical AG
	Gewerbestr. 37
	75217 Birkenfeld
	Deutschland
Phone:	+49 (0)7082 7916 0
Fax:	+49 (0)7082 7916 999
E-mail:	info@stratec.com
Internet:	www.stratec.com
ISIN:	DE0007289001
WKN:	728900
Listed:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

123490  09.05.2011